CITIUS PHARMACEUTICALS INC's ticker is CTXR and the CUSIP is 17322U207. A total of 61 filers reported holding CITIUS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.08 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,831,287 | -41.5% | 2,675,375 | +2.6% | 0.00% | – |
| Q2 2023 | $3,129,639 | +99.8% | 2,608,033 | +94.8% | 0.00% | – |
| Q1 2023 | $1,566,369 | +148794.4% | 1,338,777 | +0.5% | 0.00% | – |
| Q4 2022 | $1,052 | -99.9% | 1,332,623 | +0.7% | 0.00% | – |
| Q3 2022 | $1,601,000 | +32.9% | 1,323,296 | +1.0% | 0.00% | – |
| Q2 2022 | $1,205,000 | -70.4% | 1,310,059 | -42.3% | 0.00% | -100.0% |
| Q1 2022 | $4,067,000 | +28.9% | 2,272,145 | +10.9% | 0.00% | – |
| Q4 2021 | $3,155,000 | -27.1% | 2,049,218 | -3.8% | 0.00% | -100.0% |
| Q3 2021 | $4,326,000 | -34.8% | 2,131,122 | +11.8% | 0.00% | 0.0% |
| Q2 2021 | $6,631,000 | +336.2% | 1,905,508 | +123.1% | 0.00% | – |
| Q1 2021 | $1,520,000 | +934.0% | 854,207 | +489.3% | 0.00% | – |
| Q4 2020 | $147,000 | -2.0% | 144,949 | 0.0% | 0.00% | – |
| Q3 2020 | $150,000 | +92.3% | 144,949 | +109.3% | 0.00% | – |
| Q2 2020 | $78,000 | – | 69,247 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Inspire Advisors, LLC | 196,867 | $181,000 | 0.05% |
| Wealth Advisory Solutions, LLC | 156,850 | $144,000 | 0.04% |
| Horst & Graben Wealth Management LLC | 75,722 | $70,000 | 0.02% |
| Ergoteles LLC | 451,890 | $416,000 | 0.01% |
| Miller Investment Management, LP | 50,000 | $46,000 | 0.01% |
| Virtu Financial LLC | 81,410 | $75,000 | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 17,342 | $16,000 | 0.00% |
| Kestra Advisory Services, LLC | 71,102 | $65,000 | 0.00% |
| Csenge Advisory Group | 15,000 | $14,000 | 0.00% |
| Qube Research & Technologies Ltd | 121,281 | $112,000 | 0.00% |